Betamethasone Dose for Preterm Labor: What to Expect

The standard betamethasone course for preterm labor is two injections of 12 mg each, given into a muscle 24 hours apart, for a total of 24 mg. This protocol has been used for decades and remains the recommended regimen across major obstetric guidelines worldwide. If your care team has told you that you need steroid shots because preterm delivery looks likely, this is almost certainly what they mean. The details beyond that headline, though, matter: how fast the drug starts working, what happens if you deliver before the second shot, how your body and your baby’s monitoring may temporarily change, and whether repeat courses are ever warranted.

The Standard Two-Dose Protocol

Betamethasone for fetal lung maturation is given as an intramuscular injection, usually in the thigh or buttock. The first 12 mg dose is followed by a second 12 mg dose exactly 24 hours later. European perinatal guidelines confirm this same regimen and note that dexamethasone (a closely related steroid) can be used as an alternative at the same total dose, split into either two or four injections.¹ In most hospitals, betamethasone is the default choice.

The formulation used in practice is a 1:1 mixture of two forms of the drug: betamethasone phosphate, which releases quickly, and betamethasone acetate, which forms a slow-release depot at the injection site. Pharmacokinetic studies show that the phosphate component peaks in the blood within about half an hour, while the acetate component extends measurable drug levels for days afterward.² This dual-release design is part of why the two shots are spaced a full day apart rather than given closer together.

Some women report discomfort at the injection site. In a large randomized trial comparing betamethasone with dexamethasone, about 3% of women receiving betamethasone reported injection-site pain, compared with about 1% receiving dexamethasone.³ The soreness is temporary. Beyond injection-site pain, the steroid can cause a temporary rise in blood sugar, a flushed feeling, and sometimes mild insomnia for a night or two. These effects are short-lived and resolve once the drug clears.

How Fast the Injections Start Working

One of the most common worries is whether there will be enough time for the steroids to help. The reassuring answer is that benefits begin earlier than many people expect. A large analysis published in 2025 found that steroid exposure was linked to lower newborn mortality starting as early as two hours after the first dose. The benefit deepened and reached a plateau around 12 hours, where it remained stable for roughly the first two weeks after administration. After that, the protective effect gradually faded and was no longer detectable about four to five weeks out.⁴

A systematic review looking at the relationship between the time from steroid injection to birth and newborn outcomes confirmed that an optimal window exists, though the exact boundaries varied across studies.⁵ The practical takeaway is that even partial exposure helps, and the classic teaching that “you need 48 hours for full benefit” should not be interpreted as “anything less than 48 hours is useless.”

What If You Deliver Before the Second Shot

This is a real and common scenario. Preterm labor does not always wait for the dosing schedule to finish. Evidence from extremely preterm infants shows that even a single dose matters. A study of infants born before 28 weeks found that for every additional hour between the first betamethasone injection and delivery, survival to hospital discharge improved by roughly 1%, and survival without major complications also improved by about 1% per hour.⁶ That incremental gain continued in a steady, linear fashion across the hours measured. The message for families is clear: if there is any chance of getting the first injection before delivery, it is worth doing.

Temporary Changes to Fetal Heart Rate Monitoring

After a betamethasone course, fetal heart rate monitoring often looks different for a few days, and this can be alarming if nobody explains it ahead of time. Studies have consistently shown that betamethasone temporarily lowers the baby’s baseline heart rate and reduces the normal beat-to-beat variability. These changes are most noticeable between 24 and 36 hours after the drug is given and return to normal by about 72 hours.⁷

Earlier research found that in about a third to nearly half of cases, fetal heart rate variability temporarily dips below the normal range for gestational age.⁸ Fetal breathing movements may also become largely absent for a day or so. The concern is that these changes can look like fetal distress on a monitor strip if the clinical team is not aware that steroids were recently given. One study specifically cautioned that the reduction in fetal movements and heart rate variability “may erroneously be interpreted as deterioration of the fetal condition.”⁹ In all studies, everything returned to baseline within about four days, with no adverse outcomes linked to the temporary changes. Still, it is worth asking your care team about this in advance so a quiet monitoring strip does not trigger unnecessary panic.

Blood Sugar Effects and Diabetes Considerations

Betamethasone temporarily raises blood glucose in all pregnant women, but the effect is dramatic in women who already have diabetes. In a prospective study of women with diabetes who received betamethasone, only about 35% of blood glucose readings in the 72 hours after the first dose fell within target range. Insulin requirements climbed steeply: a median increase of 50% on the first day, doubling by day two, and rising even further on day three.¹⁰ For women with gestational diabetes, the hyperglycemia can also affect the baby. A study using an intravenous insulin protocol designed specifically for pregnancy showed that tightly controlling maternal blood sugar after betamethasone reduced the rate of neonatal hypoglycemia, which is one of the few interventions shown to do so.¹¹

If you have diabetes and are given betamethasone, expect your medical team to monitor your blood sugar closely and increase your insulin aggressively for several days. This is routine and manageable, but it requires planning.

Neonatal Hypoglycemia After Late Preterm Steroids

For babies born after late preterm steroid exposure, low blood sugar is the most commonly discussed trade-off. The landmark ALPS trial (Antenatal Late Preterm Steroids) found that betamethasone given between 34 and 36 weeks reduced respiratory complications compared with placebo, but neonatal hypoglycemia was significantly more common in the steroid group, at 24% compared with 15%.¹² A separate study found even starker numbers: babies exposed to late preterm corticosteroids were more than twice as likely to be hypoglycemic, and admissions to the NICU specifically for low blood sugar were roughly four to five times more likely in the steroid-exposed group.¹³

This is a real risk that factors into clinical decision-making, particularly for women with pre-existing diabetes. The Society for Maternal-Fetal Medicine specifically recommends against late preterm corticosteroids in women with pregestational diabetes because of the compounded hypoglycemia risk.¹⁴ For women without diabetes carrying a singleton pregnancy between 34 and 36 weeks who are truly likely to deliver within the next seven days, the recommendation is to offer the steroid course while counseling about both the respiratory benefits and the hypoglycemia risk.

Late Preterm Steroids Are Not Always Helpful

The evidence on betamethasone given after 34 weeks is genuinely mixed. The ALPS trial showed a clear benefit for the primary respiratory outcome, but other studies have found the opposite. One trial of betamethasone in late preterm neonates (34 to 36 weeks) found that treated babies actually had higher rates of respiratory distress syndrome and needed more respiratory support than untreated babies.¹⁵ The study’s authors concluded that betamethasone in the late preterm period had no benefit for lung maturity and may have caused harm.

This disagreement in the literature matters. The ALPS trial remains the largest and best-designed study on the topic, and it drives most guidelines, but the conflicting evidence means that some institutions are more cautious about late preterm steroids than others. If your hospital proposes betamethasone at 35 or 36 weeks, asking about the specific reasoning and the trade-off with neonatal hypoglycemia is a reasonable conversation to have.

Repeat and Rescue Courses

Sometimes delivery does not happen when expected, and a woman who received betamethasone weeks ago remains at risk for preterm birth. The question of whether to give another round of steroids has been studied extensively. A Cochrane systematic review found that repeat doses reduced respiratory distress syndrome and serious infant illness, but the treated babies were born slightly lighter on average. Once researchers adjusted for gestational age, the birthweight difference disappeared. At early childhood follow-up, there were no meaningful differences in survival, disability, or growth between children who had received repeat courses and those who had not.¹⁶

One long-term follow-up study did note a numerically higher rate of cerebral palsy in the repeat-dose group compared with placebo, though the difference was not statistically significant. The authors flagged it as a concern warranting further study.¹⁷ A secondary analysis following children to age six through eight found no differences in survival free of disability between those who received repeated betamethasone and those who received placebo, including in babies who had fetal growth restriction.¹⁸ Current practice generally allows a single “rescue” course if more than one to two weeks have passed since the initial course and delivery still appears imminent, but routine repeated courses are avoided.

For very early preterm births specifically, there is evidence that the benefit of the first betamethasone course against severe brain bleeds fades over time, but a timely second course can restore it.¹⁹

When Membranes Have Already Ruptured

Preterm premature rupture of membranes (often called PPROM) raises a specific question: is betamethasone still safe and effective when the protective amniotic barrier is broken and infection risk is elevated? The answer is yes. A study of women with PPROM found that a single course of betamethasone was independently associated with a large reduction in both respiratory distress syndrome and severe brain hemorrhage, without increasing rates of early neonatal sepsis, chorioamnionitis, or endometritis.²⁰

Even when infection is already present, the steroids still appear to help. A meta-analysis of antenatal steroid use in the setting of chorioamnionitis found that steroids were associated with reduced mortality, less respiratory distress, and fewer severe brain bleeds in the newborn, regardless of whether the infection was confirmed by tissue examination or by clinical signs.²¹ This finding has been important in reassuring clinicians that steroids should not be withheld simply because infection is suspected.

Betamethasone Versus Dexamethasone

You may hear that dexamethasone is sometimes used instead. The two drugs are very closely related, and head-to-head comparisons have found no meaningful clinical difference. A systematic review and network meta-analysis reported essentially identical outcomes between the two for neonatal death, neurodevelopmental disability, brain hemorrhage, and birthweight.²² The large ASTEROID trial confirmed this, finding similar rates of death or neurosensory disability at age two between the two steroid groups.³ The choice between them often comes down to local availability and cost. In many low- and middle-income countries, dexamethasone is more accessible, and guidelines endorse either drug.

Twin Pregnancies

Women carrying twins sometimes wonder whether the standard dose is enough. There is pharmacokinetic evidence suggesting it may not be ideal. A study comparing drug levels in twin versus singleton pregnancies found that betamethasone was cleared faster in twin pregnancies, with a significantly shorter half-life of about seven hours compared to nine hours in singleton pregnancies.²³ The researchers cautioned that drug levels might drop below the therapeutic threshold sooner in twin pregnancies. Despite this pharmacokinetic concern, the standard dosing protocol is still used for twins in clinical practice. No consensus exists on whether dose adjustments are needed, and the question remains an active area of research.

Long-Term Outcomes for Children

For very preterm babies, the long-term evidence is reassuring. A meta-analysis covering more than 1.25 million children found that a single course of antenatal corticosteroids in extremely preterm births was associated with a meaningful reduction in neurodevelopmental impairment.²⁴ The picture is more complicated for babies who ended up being born later than expected. In that same analysis, children born at late preterm gestations after steroid exposure had a slightly elevated rate of investigation for neurocognitive disorders, and children ultimately born at full term after steroid exposure had a higher rate of mental or behavioral disorders. The certainty of evidence for these later-birth findings was rated low, meaning the association could reflect confounding factors rather than a direct drug effect, but it does reinforce the principle that steroids should only be given when preterm delivery is genuinely likely.

Separately, prenatal betamethasone exposure has been linked to reduced hearing impairment and better overall neurodevelopmental status in extremely low birth weight infants compared with no steroid exposure.²⁵

Access in Lower-Resource Settings

Antenatal corticosteroids are among the most cost-effective interventions in perinatal medicine. The drugs themselves are inexpensive and appear on the WHO essential medicines list. Yet their use in low- and middle-income countries, where the majority of the world’s preterm births occur, remains far below what it should be. A 2025 analysis described this underuse as “a huge missed opportunity” that fails basic ethical criteria for health resource allocation.²⁶ Modeling suggests that scaling up corticosteroid use in these settings would be cost-effective, though real-world evidence from lower-resource environments remains thin.²⁷ The barrier is not the drug’s price; it is the health-system infrastructure needed to correctly identify women at risk, administer the steroid in time, and monitor the mother and baby afterward. Efforts to close this gap are ongoing but far from finished.